Search
Indecainide
go.drugbank.com/drugs/DB00192ApprovedIndecainide is a rarely used antidysrhythmic. … Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics
Bupranolol
go.drugbank.com/drugs/DB08808ExperimentalBupranolol is a non-selective beta blocker with potency similar to [propanolol]. It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnDaclizumab is a composite of human (90%) and murine (10%) antibody sequences. … Although Zinbryta (daclizumab) was available for patients as needed until 30 April 2018, Biogen and Abbvie announced a voluntary withdrawal of their product Zinbryta (daclizumab) from the global market
Bambermycins
go.drugbank.com/drugs/DB11377ExperimentalVet approvedThey are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
Synonyms: Moenomycin ALixmabegagene relduparvovec
go.drugbank.com/drugs/DB16816InvestigationalLixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). … It is under development for the treatment of GM1 gangliosidosis.[L45929]
Emodepside
go.drugbank.com/drugs/DB11403InvestigationalVet approvedEmodepside is an anthelmintic drug that is effective against a number of gastrointestinal nematodes, is licensed for use in cats and belongs to the class of drugs known as the octadepsipeptides, a relatively
Tricaine
go.drugbank.com/drugs/DB11552ExperimentalVet approvedTricaine (as tricaine methanesulfonate) is white powder used for anesthesia, sedation, or euthanasia of fish. … It is also the only anesthetic licensed in the United States for use in fin fish that are intended for human consumption.
Brodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A Antagonists